[Federal Register Volume 62, Number 43 (Wednesday, March 5, 1997)]
[Notices]
[Page 10063]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-5322]
[[Page 10063]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Advertisement of an Opportunity To Investigate the Effect of
Nitroxide Compounds on Diseases Relating to Stresses of Aging
AGENCY: National Institute on Aging, NIH.
ACTION: Advertisement of an opportunity.
-----------------------------------------------------------------------
SUMMARY: The National Institute on Aging is seeking a Cooperative
Research and Development Agreement (CRADA) with a pharmaceutical
company to investigate the effect of nitroxide compounds on diseases
related to the stresses of aging.
The Collaborator must be able to collaborate with NIA staff to
explore the effect nitroxides have on diseases of aging. The
Collaborator must have a demonstrated record of success in privately
producing nitroxide compounds suitable for pharmaceutical application,
as well as a reputation for excellence in research.
The term of the CRADA will be up to five (5) years.
DATES: Interested parties should notify this office in writing of their
intent to file a formal proposal no later than May 5, 1997. Formal
proposals must be submitted to this office no later than June 3, 1997.
ADDRESSES: Inquiries and proposals regarding this opportunity should be
addressed to Bruce D. Goldstein, J.D., (Tel. #301-496-0477, FAX # 301-
402-2177), Office of Technology Development, National Center Institute,
Executive Plaza South, Suite 450, 6120 Executive Blvd. MSC 7182,
Bethesda, Maryland, 20892.
SUPPLEMENTARY INFORMATION: A CRADA is the anticipated joint agreement
to be entered into by NIA pursuant to the Federal Technology Transfer
Act of 1986, as amended by the National Technology Transfer Act (Pub.
L. #104-1993 (1996)) and by Executive Order 12591 of October 10, 1987.
NIA is presently exploring the protective effects of nitroxide
compounds on oxyradical-induced oxidative stress, to the extent such
stresses are related to diseases of aging.
Under the present proposal, the goal of the CRADA will be
research into, and development of, the following technology:
Assessment of the qualitative and quantitative influence
nitroxide compounds have on various aspects of the aging process.
Development of new nitroxide compounds having in vivo
inhibitive effect on the formation of oxyradicals.
Development of new nitroxide compounds that enhance
neuronal function and performance of aged animals.
Party Contributions
The role of NIA includes the following:
(1) Provide staff, expertise, & materials for the development of
the desired compounds;
(2) Evaluate the work product of Collaborator to ensure progress
toward meeting the CRADA goals; and
(3) Provide work space, expertise, and equipment for production of
any prototypes developed.
The role of the successful Collaborator will include the following:
(1) Provide expertise on biological aging mechanisms and assistance
in the development of nitroxide compounds likely to have therapeutic
value;
(2) Provide funding, as necessary, in support of production and
dissemination of the desired compounds; and
(3) Provide resources and expertise to market any products
developed.
Selection Criteria
Proposals submitted for consideration should fully address each of
the following qualifications:
(1) Expertise:
(A) Demonstrated expertise in developing and producing nitroxide
compounds;
B. Demonstrated expertise on biological aging mechanisms;
C. Demonstrated ability to secure national and international
marketing and distribution of nitroxide compounds;
D. Demonstrated expertise in overseeing all aspects of product
development; and
E. Demonstrated intellectual ability to participate in the research
and commercial ability to guide development of the results into a
viable product line.
(2) Physical Resources:
A. An established headquarters with offices, space, and equipment;
B. Access to the organization during business hours by telephone,
mail, e-mail, the Internet, and other evolving technologies; and
C. Sufficient financial resources to support the current activities
of the CRADA to meet the needs of NIA.
Dated: February 18, 1997.
Thomas D. Mays,
Director, Office of Technology Development, NCI, NIH.
[FR Doc. 97-5322 Filed 3-4-97; 8:45 am]
BILLING CODE 4140-01-M
